Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.Read more about Immatics on our homepage: https://immatics.com/Find us also on:Instagram: https://www.instagram.com/immatics/YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSALegal notice: https://immatics.com/imprint/